EUVIMEDEUVIMED entdecken
Open Access

Use of overnight metyrapone test in suspected secondary adrenal insufficiency: A retrospective single centre‐study

Jasmine Saini iD, Raul Gregg Garcia, Justine Herndon iD, Dana Erickson, Lucinda Gruber iD, Irina Bancos iD

Clinical Endocrinology · 2024-03 · 100 (3) · 203-211

DOI: 10.1111/cen.14989 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 24.11.2023. Verfasst von Jasmine Saini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, New York, USA. Hauptthemen laut MEDLINE: Metyrapone, Adrenal Insufficiency. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Overnight metyrapone test (OMT) is a dynamic test used to diagnose secondary adrenal insufficiency (SAI). Data on OMT use and its safety are scarce. We aimed to describe the indications and safety of outpatient OMT and compare OMT to the cosyntropin stimulation test (CST).

Design

Single‐centre retrospective study of adult patients undergoing OMT between 1 April 2018 and 27 January 2023.

Measurements

OMT‐related adverse events, post‐OMT diagnosis of SAI, and OMT comparison to CST.

Results

OMT was performed in 114 patients (81, 71% women) at a median age of 48 (interquartile range 37–58). The pretest probability for SAI was low in 52 (46%) patients, moderate in 48 (42%) patients and high in 14 (12%) patients. Adverse events were reported in 7 (6.1%) patients and were mild except for one hospitalization. No baseline or OMT‐related factors were associated with the development of adverse events. Prevalence of the OMT‐based SAI diagnosis was 26 (23%) and 47 (46%) using 11‐deoxycortisol cutoff

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetyraponeAdrenal InsufficiencyAdultHumansFemaleMaleRetrospective StudiesCortodoxoneCosyntropinHydrocortisone

Stichwörter der Autor:innen

accuracyadverse eventcortisolcosyntropin stimulationdiagnosis

Substanzen

MetyraponeCortodoxoneCosyntropinHydrocortisone

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, New York, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, New York, USA.

ORCID-Profile: Jasmine Saini, Justine Herndon, Lucinda Gruber, Irina Bancos

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Saini, J., Garcia, R. G., Herndon, J., Erickson, D., Gruber, L., & Bancos, I. (2024). Use of overnight metyrapone test in suspected secondary adrenal insufficiency: A retrospective single centre‐study. Clinical Endocrinology, 100(3), 203-211. https://doi.org/10.1111/cen.14989

Vancouver

Saini J, Garcia RG, Herndon J, Erickson D, Gruber L, Bancos I. Use of overnight metyrapone test in suspected secondary adrenal insufficiency: A retrospective single centre‐study. Clinical Endocrinology. 2024;100(3):203-211. doi:10.1111/cen.14989

BibTeX
@article{Saini2024,
  author = {Saini, Jasmine and Garcia, Raul Gregg and Herndon, Justine and Erickson, Dana and Gruber, Lucinda and Bancos, Irina},
  title = {Use of overnight metyrapone test in suspected secondary adrenal insufficiency: A retrospective single centre‐study},
  journal = {Clinical Endocrinology},
  year = {2024},
  volume = {100},
  number = {3},
  pages = {203--211},
  doi = {10.1111/cen.14989}
}
Kostenlos starten →